Erminia Romano

Dr. Erminia Romano

CRUK Manchester
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2017 in Nature Methods
Verified
Journal Article
Closed access
ECEV-TRACK Consortium
EV-TRACK Consortium
JDJan Van Deun
Jan Van Deun
PMPieter Mestdagh
Pieter Mestdagh
PAPatrizia Agostinis
Patrizia Agostinis
ÖAÖzden Akay
Özden Akay
AHAn Hendrix
An Hendrix

20 November 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Abhishek GargAbhishek Garg
Abhishek Garg
LGLorenzo Galluzzi
Lorenzo Galluzzi
LALionel Apetoh
Lionel Apetoh
TBThais Baert
Thais Baert
RBRaymond B. Birge
Raymond B. Birge
PAPatrizia Agostinis
Patrizia Agostinis
The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called “damage-associated molecular patterns” (DAMPs). The emission of DAMPs and other immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. Although ICD has been characterized with increased precision since its discovery, several questions remain to be addressed. Here, we summarize and tabulate the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.

1 January 2015 in The International Journal of Developmental Biology
Verified
Journal Article
Closed access
PDF file
Abhishek GargAbhishek Garg
Abhishek Garg
ADAleksandra M. Dudek-Peric
Aleksandra M. Dudek-Peric
Erminia RomanoErminia Romano
Erminia Romano
PAPatrizia Agostinis
Patrizia Agostinis
Currently, it is widely acknowledged that a proactive anticancer immunosurveillance mechanism takes part in the rejection of neoplastic lesions before they progress towards a benign or malignant tumour. However in cases of very aggressive neoplastic lesions consisting of cells with high mutational diversity, cancer cell variants might be formed that are capable of evading host defence systems against uncontrolled proliferation and anticancer immunosurveillance. This is mainly accomplished through the exhibition of low immunogenicity, which is a particularly important stumbling block in the revival of long-lasting as well as stable anticancer immunity. Recently, it has emerged emphatically that inciting a cancer cell death routine, associated with the activation of danger signalling pathways evoking emission of damage-associated molecular patterns (DAMPs), markedly increases the immunogenicity of dying cancer cells. This cell death pathway has been termed “immunogenic cell death” (ICD). In the present review we introduce this concept and discuss its characteristics in detail. We also discuss in detail the various molecular, immunological and operational determinants of ICD.

19 February 2016 in Cell Death & Differentiation
Verified
Journal Article
Closed access
Abhishek GargAbhishek Garg
Abhishek Garg
Erminia RomanoErminia Romano
Erminia Romano
NRN Rufo
N Rufo
PAPatrizia Agostinis
Patrizia Agostinis

13 January 2015 in Photochemical & Photobiological Sciences
Verified
Journal Article
Closed access
PDF file
Abhishek GargAbhishek Garg
Abhishek Garg
HMHannelore Maes
Hannelore Maes
Erminia RomanoErminia Romano
Erminia Romano
PAPatrizia Agostinis
Patrizia Agostinis
Autophagy is a major catabolic pathway in a eukaryotic cell, employed for cellular self-degradation of obsolete or damaged cytoplasmic components serving as a major quality control and recycling mechanism that supports cell survival. Autophagy is fundamentally a cytoprotective and pro-survival process yet in general, it has become clear through a number of studies that autophagy has an exceedingly contextual role in cancer biology; conditional on which phase, location or type of oncogenic trigger and/or therapy is under consideration, the role of autophagy could end up fluctuating from pro- to anti-tumourigenic. Numerous studies have revealed that, contingent on the photosensitiser under consideration, autophagy triggered by PDT either adds to therapy resistance (by suppressing cell death) or vulnerability (by enabling autophagic cell death). Beyond cell death regulation, cancer cell-associated autophagy also supports resistance against PDT by reducing anticancer immune effector mechanisms. In this review, we have concisely described the state-of-the-art and the prevailing gap-in-knowledge vis-à-vis the role of PDT-triggered autophagy in cancer therapy resistance or susceptibility.

26 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Erminia RomanoErminia Romano
Erminia Romano
JHJamie Honeychurch
Jamie Honeychurch
TITimothy Illidge
Timothy Illidge
Radiotherapy (RT) is highly effective at directly killing tumor cells and plays an important part in cancer treatments being delivered to around 50% of all cancer patients. The additional immunomodulatory properties of RT have been investigated, and if exploited effectively, have the potential to further improve the efficacy of RT and cancer outcomes. The initial results of combining RT with immunomodulatory agents have generated promising data in pre-clinical studies, which has in turn led to a large number of RT and immunotherapy clinical trials. The overarching aim of these combinations is to enhance anti-tumor immune responses and improve responses rates and patient outcomes. In order to maximize this undoubted opportunity, there remain a number of important questions that need to be addressed, including: (i) the optimal RT dose and fractionation schedule; (ii) the optimal RT target volume; (iii) the optimal immuno-oncology (IO) agent(s) to partner with RT; (iv) the optimal site(s)/route(s) of administration of IO agents; and finally, the optimal RT schedule. In this review, we will summarize progress to date and identify current gaps in knowledge that need to be addressed in order to facilitate effective clinical translation of RT and IO agent combinations.